AC Immune Strikes Potential $509 Million Development Deal

January 12, 2015 11:19 AM

5
0

ZURICH--Swiss biotech company AC Immune said on Monday it had struck a deal potentially worth $509 million with a unit of Johnson & Johnson ( JNJ ) to develop vaccines against Alzheimer's disease, the most common form of dementia.

Janssen Pharmaceuticals, Inc. will help further develop AC Immune's leading therapeutic vaccine, dubbed ACI-35, the Lausanne-based company said. The vaccine is currently in an early-stage clinical trial.